Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/handle/123456789/8972
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPenitente, Arlete Rita-
dc.contributor.authorLeite, Ana Luísa Junqueira-
dc.contributor.authorCosta, Guilherme de Paula-
dc.contributor.authorBajracharya, Deena Shrestha-
dc.contributor.authorHorta, Aline Luciano-
dc.contributor.authorNatali, Antônio José-
dc.contributor.authorNeves, Clóvis Andrade-
dc.date.accessioned2017-10-18T15:05:49Z-
dc.date.available2017-10-18T15:05:49Z-
dc.date.issued2015-
dc.identifier.citationPENITENTE, A. R. et al. Enalapril in combination with benznidazole reduces cardiac inflammation and creatine kinases in mice chronically infected with Trypanosoma cruzi. The American Journal of Tropical Medicine and Hygiene, v. 93, p. 976-982, 2015. Disponível em: <http://www.ajtmh.org/docserver/fulltext/14761645/93/5/976.pdf?expires=1500908996&id=id&accname=guest&checksum=C1AF0176A7057CAFD489718527489A0B>. Acesso em: 05 ago. 2017.pt_BR
dc.identifier.issn1476-1645-
dc.identifier.urihttp://www.repositorio.ufop.br/handle/123456789/8972-
dc.description.abstractThe protozoan Trypanosoma cruzi triggers an inflammatory process in mammalian heart causing events such as fibrosis, changes in the architecture and functionality in this organ. Enalapril, an angiotensin II-converting enzyme inhibitor, is a drug prescribed to ameliorate this heart dysfunction, and appears to exert a potential role in immune system regulation. Our aim was to evaluate the chronic cardiac inflammatory parameters after therapeutic treatment with enalapril and benznidazole in C57BL/6 mice infected with the VL-10 strain of T. cruzi. After infection, animals were treated with oral doses of enalapril (25 mg/kg), benznidazole (100 mg/kg), or both during 30 days. Morphometric parameters and levels of chemokines (CCL2, CCL5), IL-10, creatine kinases (CKs), and C-reactive protein were evaluated in the heart and serum at the 120th day of infection. Enalapril alone or in combination with benznidazole did not change the number of circulating parasites, but reduced cardiac leukocyte recruitment and total collagen in the cardiac tissue. Interestingly, the combination therapy (enalapril/benznidazole) also reduced the levels of chemokines, CK and CK-MB, and C-reactive proteins in chronic phase. In conclusion, during the chronic experimental T. cruzi infection, the combination therapy using enalapril plus benznidazole potentiated their immunomodulatory effects, resulting in a low production of biomarkers of cardiac lesionspt_BR
dc.language.isoen_USpt_BR
dc.rightsrestritopt_BR
dc.titleEnalapril in combination with benznidazole reduces cardiac inflammation and creatine kinases in mice chronically infected with Trypanosoma cruzi.pt_BR
dc.typeArtigo publicado em periodicopt_BR
dc.identifier.uri2http://www.ajtmh.org/docserver/fulltext/14761645/93/5/976.pdf?expires=1508337530&id=id&accname=guest&checksum=1FE84F7A51FFE8007522E5B64B985F3Ept_BR
dc.identifier.doihttps://doi.org/10.4269/ajtmh.15-0237-
Appears in Collections:DEMSC - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_EnalaprilCombinationBenznidazole.pdf1,09 MBAdobe PDFView/Open    Request a copy


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.